ClinicalTrials.gg
RecruitingNCT06976944PRELUDEUpdated Jul 13, 2026

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

A Phase 2 interventional study of Pembrolizumab and Paclitaxel in Recurrent Triple-Negative Breast Cancer, sponsored by Yukinori Ozaki. Recruiting at 14 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Yukinori Ozaki · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing bevacizumab in Triple Negative Breast Neoplasms — 6 open to participants now, 6 under way, none of them phase 3. Bevacizumab · Triple Negative Breast Neoplasms.

Planned enrollment
13th of 14
24 · median 57
Started
2025
with 1 other
Phase 2
12 of 14
4 open now
Registered
13th of 14
by date

Among the 14 studies testing bevacizumab in Triple Negative Breast Neoplasms, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 12 in phase 2, and was the 13th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

6 of the 14 studies testing bevacizumab in Triple Negative Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bevacizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

  • Breast cancer is histologically divided into non-invasive (approximately 10%) and invasive (approximately 90%), with invasive cancer being the target of chemotherapy. Invasive carcinoma is classified into four subtypes according to the expression levels of hormone receptor (HR) and human epidermal growth factor receptor type 2 (HER2). Among them, triple negative breast cancer accounts for 10% of invasive cancers and is the subtype with the poorest prognosis.
  • For triple negative breast cancer that is operable, chemotherapy with pembrolizumab is administered either preoperatively or postoperatively (perioperative period). For recurrent triple negative breast cancer , combination chemotherapy with multiple agents is the standard of care, especially in the case of PD-L1-positive patients, chemotherapy with an immune checkpoint inhibitor related to PD-1 (pembrolizumab or atezolizumab) is administered.
  • Although the KEYNOTE355 trial demonstrated the efficacy of pembrolizumab plus paclitaxel therapy in patients with PD-L1-positive triple negative breast cancer in postoperative relapse, this trial did not include patients who received pembrolizumab in the perioperative period. Therefore, it is not known if there is any benefit to re-administering pembrolizumab to these patients after relapse.
  • Bevacizumab is used as standard therapy for triple negative breast cancer in combination with paclitaxel. Bevacizumab itself is an anti-tumor agent that inhibits angiogenesis, but has also been reported to activate immunity against cancer, suggesting that it may enhance the effect of pembrolizumab.

Based on the above, the investigators planned this trial to evaluate whether pembrolizumab + paclitaxel + bevacizumab therapy is more effective than pembrolizumab + paclitaxel therapy in PD-L1-positive triple negative breast cancer patients who relapse after receiving immune checkpoint inhibitors in the perioperative period.

03

Conditions studied

  • Recurrent Triple-Negative Breast Cancer

Keywords

  • Recurrent Triple-Negative
  • Breast Cancer
  • checkpoint inhibitor
  • angiogenesis inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female participants who are 18 years of age or older on the day of signing with or cytologically confirmed diagnosis of invasive breast cancer will be enrolled in this study.
  2. Participants have been confirmed to be ER negative, negative according to the latest ASCO/CAP criteria. However, it does not matter whether the result is positive or negative for PgR.
  3. Participants have been confirmed to be positive in each site's evaluation using specimen or surgical specimen.
  4. Participants who have received not more than 1 prior chemotherapy regimen (including those with no prior chemotherapy) for recurrent breast cancer, excluding trial drugs of this clinical trial. (Participants with prior paclitaxel or bevacizumab for recurrent breast cancer are excluded.) However, prior treatment with Olaparib for recurrence or unresectable advanced cancer in participants with BRCA gene pathogenic variant is allowed (not counted as 1 regimen).
  5. Participants must have recurred after treatment with an anti-PD-1/PD-L1 antibody administered as monotherapy or in combination with other ICIs or chemotherapies as a perioperative drug therapy for triple negative breast cancer.
  6. Have an performance status of 0 to 1.

Exclusion criteria

Exclusion Criteria:

  1. Participants with progressive disease on or clinically diagnosed during preoperative ICI and chemotherapy.
  2. Known additional that is progressing or has required active treatment within the past 3 years prior to enrollment.
  3. Has known active and/or carcinomatous meningitis.
  4. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Pembrolizumab + paclitaxel + bevacizumab

    Drug: Pembrolizumab · Drug: Paclitaxel · Drug: Bevacizumab

  • Active comparator
    Pembrolizumab + paclitaxel

    Drug: Pembrolizumab · Drug: Paclitaxel

Interventions

  • Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria. Pembrolizumab: Intravenous infusion(400 mg/body, every 6 weeks starting on Day 1 of Cycle 1)

  • Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria. Paclitaxel: Intravenous infusion(90 mg/m\^2, on Days 1, 8, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)

  • Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria. Bevacizumabl: Intravenous infusion(10 mg/kg, on Days 1, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: Through protocol treatment discontinuation, approximately 9 months

Secondary outcomes

  1. Overall response rate

    Time frame: Through protocol treatment discontinuation, approximately 9 months

  2. Overall survival

    Time frame: Through study completion, approximately 3.5 years

  3. Disease control rate

    Time frame: Through protocol treatment discontinuation, approximately 9 months

  4. Incidence of adverse events

    Time frame: Until 1 month after protocol treatment discontinuation, approximately 10 months

07

Study locations

14 of 14 sites recruiting
  • National Hospital Organization Nagoya Medical Center
    Nagoya, Aichi-ken 460-0001, Japan
    Recruiting
    • Chiyoe Kitagawa · Contact+81-52-951-1111
    • Chiyoe Kitagawa · Principal investigator
  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
    Recruiting
    • Madoka Iwase · Contact+81-52-741-2111
    • Madoka Iwase · Principal investigator
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
    Recruiting
    • Kazuki Nozawa · Contact+81-52-851-5511
    • Kazuki Nozawa · Principal investigator
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
    Recruiting
    • Chikako Funasaka · Contact+81-4-7133-1111
    • Chikako Funasaka · Principal investigator
  • Gifu University Hospital
    Gifu, Gifu 501-1194, Japan
    Recruiting
    • Manabu Futamura · Contact+81-58-230-6000
    • Manabu Futamura · Principal investigator
  • Hiroshima University Hospital
    Hiroshima, Hiroshima 734-8551, Japan
    Recruiting
    • Hideo Shigematsu · Contact+81-82-257-5555
    • Hideo Shigematsu · Principal investigator
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
    Recruiting
    • Tomohiro Oshino · Contact+81-11-716-1161
    • Tomohiro Oshino · Principal investigator
  • Hyogo Cancer Center
    Akashi-shi, Hyōgo 673-8558, Japan
    Recruiting
    • Koji Matsumoto · Contact+81-78-929-1151
    • Koji Matsumoto · Principal investigator
  • Okayama University Hospital
    Okayama, Okayama-ken 700-8558, Japan
    Recruiting
    • Yuko Takahashi · Contact+81-86-235-6835
    • Yuko Takahashi · Principal investigator
  • Osaka International Cancer Institute
    Osaka, Osaka 541-8567, Japan
    Recruiting
    • Takahiro Nakayama · Contact+81-6-6945-1181
    • Takahiro Nakayama · Principal investigator
  • Osaka Metropolitan University Hospital
    Osaka, Osaka 545-0051, Japan
    Recruiting
    • Shinichiro Kashiwagi · Contact+81-6-6645-2121
    • Shinichiro Kashiwagi · Principal investigator
  • Kindai University Hospital
    Sakai-shi, Osaka 590-0197, Japan
    Recruiting
    • Satomi Watanabe · Contact+81-72-288-7222
    • Satomi Watanabe · Principal investigator
  • Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
    Recruiting
    • Toshimi Takano · Contact+81-3-3520-0111
    • Yukinori Ozaki · Principal investigator
  • SHOWA Medical University Hospital
    Shinagawa-ku, Tokyo 142-8666, Japan
    Recruiting
    • Hitomi Sakai · Contact+81-3-3784-8000
    • Hitomi Sakai · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Sep 2029, 51 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 51 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 16, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06976944
Lead sponsor
Yukinori Ozaki
Responsible party
Yukinori Ozaki (Director of Breast Medical Oncology, Japanese Foundation for Cancer Research) — Sponsor-investigator
First posted
May 16, 2025
Start date
Jun 24, 2025
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Yukinori Ozaki
Contact
yukinori.ozaki@jfcr.or.jp
+81-3-3520-0111
Kazuki Nozawa
Contact
k.nozawa@med.nagoya-cu.ac.jp
+81-52-851-5511
Toshimi Takano
study chair · Cancer Institute Hospital of JFCR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion